Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking

Journal of Virology

Volumn 85, Issue 22, 2011, Pages 11791-11799

  Nam, Hyun Joo ^a,c   Gurda, Brittney L ^a,d   McKenna, Robert ^a   Potter, Mark ^b   Byrne, Barry ^b   Salganik, Maxim ^b   Muzyczka, Nicholas ^b   Agbandje McKenna, Mavis ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c The University of Texas at Dallas   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GREEN FLUORESCENT PROTEIN; MONOMER; PHOSPHOLIPASE A2;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS SEROTYPE 8; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA CONFORMATION; DNA PACKAGING; ENDOSOME; GENE REARRANGEMENT; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PH; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; VIRUS CAPSID; VIRUS GENOME; VIRUS MORPHOLOGY;

CAPSID; CRYSTALLOGRAPHY, X-RAY; DEPENDOVIRUS; ENDOSOMES; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; PROTEIN CONFORMATION;

ADENO-ASSOCIATED VIRUS; MIRIDAE; PARVOVIRUS;

EID: 80655142508     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05305-11     Document Type: Article

References (53)

1. Akache, B., et al. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-9836.
2. Akache, B., et al. 2007. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol. Ther. 15:330-339.
3. Bartlett, J. S., R. Wilcher, and R. J. Samulski. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74: 2777-2785.
4. Bhattacharyya, R., R. P. Saha, U. Samanta, and P. Chakrabarti. 2003. Geometry of interaction of the histidine ring with other planar and basic residues. J. Proteome Res. 2:255-263.
5. Bleker, S., F. Sonntag, and J. A. Kleinschmidt. 2005. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 79:2528-2540.
6. Brunger, A. T., et al. 1998. Crystallography & NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
7. Carter, B. J. 2005. Adeno-associated virus vectors in clinical trials. Hum. Gene Ther. 16:541-550.
8. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
9. Chapman, M. S., and M. Agbandje-McKenna. 2006. Atomic structure of viral particles, p. 107-123. In J. R. Kerr, S. F. Cotmore, M. E. Bloom, R. M. Linden, and C. R. Parrish (ed.), Parvoviruses. Edward Arnold, Ltd., New York, NY.
10. Cotmore, S. F., and P. Tattersall. 2007. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 70:183-232.
11. Coura Rdos, S., and N. B. Nardi. 2007. The state of the art of adenoassociated virus-based vectors in gene therapy. Virol. J. 4:99.
12. Daya, S., and K. I. Berns. 2008. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21:583-593.
13. DeLano, W. L. 2002. The PyMOL molecular graphics system. DeLano Scientific, San Carlos, CA.
14. Douar, A. M., K. Poulard, D. Stockholm, and O. Danos. 2001. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75:1824-1833.
15. Eckert, D. M., and P. S. Kim. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.
16. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
17. Flotte, T. R., and B. J. Carter. 1995. Adeno-associated virus vectors for gene therapy. Gene Ther. 2:357-362.
18. Gao, G. P., et al. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99:11854-11859.
19. Girod, A., et al. 2002. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 83:973-978.
20. Govindasamy, L., et al. 2006. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80:11556-11570.
21. Grieger, J. C., J. S. Johnson, B. Gurda-Whitaker, M. Agbandje-McKenna, and R. J. Samulski. 2007. Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J. Virol. 81:7833-7843.
22. Gruenberg, J., and F. G. van der Goot. 2006. Mechanisms of pathogen entry through the endosomal compartments. Nat. Rev. Mol. Cell Biol. 7:495-504.
23. Hansen, J., K. Qing, and A. Srivastava. 2001. Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J. Virol. 75:4080-4090.
24. Hauck, B., and W. Xiao. 2003. Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 77:2768-2774.
25. Jiang, H., et al. 2006. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108:107-115.
26. Kern, A., et al. 2003. Identification of a heparin-binding motif on adenoassociated virus type 2 capsids. J. Virol. 77:072-11081.
27. Kohlbrenner, E., et al. 2005. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 12:1217-1225.
28. Kronenberg, S., B. Bottcher, C. W. von der Lieth, S. Bleker, and J. A. Kleinschmidt. 2005. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J. Virol. 79:5296-5303.
29. Lane, M. D., et al. 2005. Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crystallogr. F 61:558-561.
30. Lebherz, C., et al. 2004. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. 6:663-672.
31. Lerch, T. F., Q. Xie, and M. S. Chapman. 2010. The structure of adenoassociated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 403:26-36.
32. Levy, H. C., et al. 2009. Heparin binding induces conformational changes in adeno-associated virus serotype 2. J. Struct. Biol. 165:146-156.
33. Lochrie, M. A., et al. 2006. Mutations on the external surfaces of adenoassociated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80:821-834.
34. Mori, S., L. Wang, T. Takeuchi, and T. Kanda. 2004. Two novel adenoassociated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330:375-383.
35. Reference deleted
36. Nam, H. J., et al. 2007. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81:12260-12271.
37. Ng, R., et al. 2010. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 84:12945-12957.
38. Opie, S. R., K. H. J. Warrington, M. Agbandje-McKenna, S. Zolotukhin, and N. Muzyczka. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77:6995-7006.
39. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 296:307-326.
40. Padron, E., et al. 2005. Structure of adeno-associated virus type 4. J. Virol. 79:5047-5058.
41. Reddy, V. S., et al. 2001. Virus Particle Explorer (VIPER), a website for virus capsid structures and their computational analyses. J. Virol. 75:11943-11947.
42. Sarkar, R., et al. 2004. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103:1253-1260.
43. Shen, X., T. Storm, and M. A. Kay. 2007. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol. Ther. 15:1955-1962.
44. Skehel, J. J., and D. C. Wiley. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:531-569.
45. Sonntag, F., S. Bleker, B. Leuchs, R. Fischer, and J. A. Kleinschmidt. 2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 80:11040-11054.
46. Sun, B., et al. 2005. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11:57-65.
47. Thomas, C. E., T. A. Storm, Z. Huang, and M. A. Kay. 2004. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78:3110-3122.
48. Wobus, C. E., et al. 2000. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74:9281-9293.
49. Wu, P., et al. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635-8647.
50. Wu, Z., et al. 2006. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80:393-11397.
51. Xie, Q., et al. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99:10405-10410.
52. Zhong, L., et al. 2008. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381:194-202.
53. Zhong, L., et al. 2008. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U. S. A. 105:7827-7832.